ORPHAI
DEAD

Serial Number

98203856

Owner

ORPHAI THERAPEUTICS INC.

Attorney

Susan N. Acquista, Esq.

Filing Date

Sep 29, 2023

Add to watchlist:

No watchlists yet
View on USPTO

ORPHAI Trademark

Serial Number: 98203856

ORPHAI is a trademark filed by ORPHAI THERAPEUTICS INC. on September 29, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

ORPHAI THERAPEUTICS INC. (3 trademarks)

530 OLD WHITFIELD STREET
GUILFORD, CT 06437

Entity Type: 03

Trademark Details

Filing Date

September 29, 2023

Registration Date

Not Registered

Goods & Services

Medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, and genetic diseases; Pharmaceutical and biopharmaceutical agents for the treatment of cancer and rare diseases, namely, Amyotrophic Lateral Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Sarcoidosis, Bronchiolitis Obliterans; Pharmaceutical and biopharmaceutical preparations for the treatment of cancer and rare diseases, namely, Amyotrophic Lateral Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Sarcoidosis, Bronchiolitis Obliterans; Pharmaceutical and biopharmaceutical agents for the treatment of cancer and rare diseases; Pharmaceutical and biopharmaceutical preparations and substances for the treatment of cancer and rare diseases; Pharmaceutical, medical, scientific, and biopharmaceutical research and development

Recorded computer software featuring deep learning algorithms and AI for pharmaceutical, medical, scientific, and biopharmaceutical research and development and analysis, none of the foregoing for design, test and implementation

Development of pharmaceutical preparations and medicines; Genetic engineering; Laboratory research in the field of gene expression; Medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, and genetic diseases; Medical, pharmaceutical, and biopharmaceutical research services; Non-downloadable computer software featuring deep learning algorithms and AI for pharmaceutical, medical, scientific, and biopharmaceutical research and development and analysis; Pharmaceutical, medical, scientific, and biopharmaceutical research and development; Providing medical and scientific research in the fields of pharmaceuticals, genetics, genome editing, gene editing, genome engineering, gene modulation, transcriptional regulation, transcriptional modulation, and genetic diseases; Providing research and development relating to pharmaceutical, medical, scientific, and biopharmaceutical; Research in the field of gene therapy; Scientific and medical research in the fields of gene, genome, and genomic editing, modulation, transcription, to develop human pharmaceutical and biopharmaceutical preparations; Scientific research for medical purposes in the field of cancerous diseases; Scientific research in the field of genetics

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Dec 2, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Dec 2, 2024 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Aug 14, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Aug 14, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 17, 2024 CNRT
ASSIGNED TO EXAMINER
May 7, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 12, 2023 NWOS
NEW APPLICATION ENTERED
Oct 3, 2023 NWAP